DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Chloride Channel Blocker for Cancer and Neuroprotection

Executive Summary: DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is a selective anion transport inhibitor cited for its ability to block ClC-Ka chloride channels (IC50 = 100 μM) and the bacterial ClC-ec1 Cl-/H+ exchanger (IC50 ≈ 300 μM) [ApexBio]. DIDS reduces spontaneous transient inward currents (STICs) in muscle and demonstrates vasodilatory effects on cerebral artery smooth muscle (IC50 = 69 ± 14 μM) [Conod et al., 2022]. It modulates TRPV1 channel function in DRG neurons, and in vivo, potentiates hyperthermia-induced tumor growth suppression when combined with amiloride. In neonatal rat models, DIDS confers neuroprotection by reducing ischemia-hypoxia-induced white matter damage via ClC-2 channel inhibition and modulation of oxidative stress markers. These findings position DIDS as a validated tool for research in cancer, neuroprotection, and vascular physiology, with precise application parameters and known limitations.

Biological Rationale

DIDS is a synthetic stilbene derivative with two isothiocyanate and two sulfonic acid groups. Its primary biological function is to inhibit anion (chloride) transport across cellular membranes. Chloride channels, such as ClC-Ka and ClC-2, regulate essential physiological processes, including cell volume, electrical excitability, and apoptosis in neuronal, vascular, and tumor cells [Conod et al., 2022]. Dysregulation of chloride flux is implicated in cancer metastasis, neurodegeneration, and vascular tone disturbances. By selectively blocking these transporters, DIDS enables mechanistic dissection of chloride-dependent pathways in diverse models. Its application provides insight into cell death, tumor microenvironment modulation, and neuroprotective strategies.

Mechanism of Action of DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid)

DIDS acts by covalently modifying lysine residues near the pore region of chloride channels, leading to rapid and often irreversible inhibition of anion flow [Conod et al., 2022]. The compound shows highest affinity for ClC-Ka (IC50 = 100 μM) and bacterial ClC-ec1 (IC50 ≈ 300 μM). DIDS also inhibits voltage-gated ClC-2 channels, reducing chloride influx and downstream cellular responses. In muscle, DIDS reduces STICs in a concentration-dependent manner. In the vascular system, DIDS induces vasodilation by blocking smooth muscle chloride currents (IC50 = 69 ± 14 μM). In neurons, DIDS modulates TRPV1 channel activity, potentiating capsaicin- or proton-induced currents in dorsal root ganglion (DRG) cells. In cancer models, DIDS disrupts mitochondrial outer membrane permeabilization, affecting apoptosis and cell fate reprogramming. Collectively, these actions make DIDS a versatile probe for dissecting chloride channel functions in health and disease.

Evidence & Benchmarks

• DIDS inhibits ClC-Ka chloride channel with an IC50 of 100 μM at 22°C in physiological buffer (ApexBio).
• DIDS blocks the bacterial ClC-ec1 Cl-/H+ exchanger with an IC50 ≈ 300 μM, measured by patch-clamp (ApexBio).
• In isolated smooth muscle, DIDS reduces STICs in a dose-dependent manner (10–100 μM); effect is reversible upon washout (Conod et al., 2022).
• DIDS induces vasodilation in pressure-constricted rat cerebral artery smooth muscle (IC50 = 69 ± 14 μM at 37°C, pH 7.4) (Conod et al., 2022).
• DIDS modifies TRPV1 channel function in DRG neurons, enhancing agonist-induced currents (capsaicin/low pH) at 30–100 μM (Conod et al., 2022).
• In vivo, DIDS combined with amiloride enhances hyperthermia-induced tumor growth suppression and delays tumor regrowth (mouse xenograft, 37–42°C, 100 μM intratumoral) (Conod et al., 2022).
• DIDS protects neonatal rat white matter from ischemia-hypoxia injury by inhibiting ClC-2, reducing ROS, iNOS, TNF-α, and caspase-3+ cell counts at 50–100 μM (Conod et al., 2022).

Applications, Limits & Misconceptions

DIDS is applied in research on chloride channel physiology, vascular tone regulation, neuroprotection, and cancer therapeutics. Its specificity enables mechanistic studies of ClC family channels and TRPV1 modulation. In oncology, DIDS is used to probe apoptosis, metastasis, and cell fate transitions. In neuroscience, it models neurodegeneration and ischemia-hypoxia responses. In vascular biology, DIDS allows analysis of smooth muscle contractility and vasodilation.

For further workflows and advanced troubleshooting, see DIDS Chloride Channel Blocker: Applied Workflows & Advanced Applications, which provides practical integration steps. This article extends that guide with detailed mechanistic evidence and quantitative benchmarks.

For strategic deployment in translational research, DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Mechanistic Rationale and Applications offers a roadmap; this dossier updates the literature with the latest in vivo findings on tumor suppression and neuroprotection.

Common Pitfalls or Misconceptions

• DIDS is not soluble in water, ethanol, or DMSO below 10 mM; improper dissolution leads to inconsistent dosing (ApexBio).
• DIDS is not recommended for long-term storage in solution; degradation can affect potency (ApexBio).
• DIDS is not selective for all chloride channels—off-target effects occur at high concentrations (>1 mM) (Conod et al., 2022).
• DIDS does not cross the blood-brain barrier efficiently in adult mammals; in vivo neuroprotection is best modeled with local delivery (Conod et al., 2022).
• DIDS is not a therapeutic agent; use is restricted to research applications only (ApexBio).

Workflow Integration & Parameters

DIDS (B7675) is supplied as a solid. For optimal solubility, dissolve in DMSO to concentrations >10 mM, using gentle warming at 37°C or ultrasonic bath for complete dissolution. Working dilutions should be prepared fresh in buffer, with final DMSO concentrations ≤0.1% to avoid cytotoxicity. Stock solutions must be stored at <-20°C and are not stable for more than 1 month. In cell-based assays, typical working concentrations range from 10–100 μM, with functional readouts (patch-clamp, calcium imaging, or viability assays) performed within 30–60 minutes of addition. For tumor or vascular models, local delivery is recommended due to limited systemic bioavailability. For comparative protocols and advanced troubleshooting, refer to DIDS: Mechanistic Insights into Chloride Channel Blockade, which analyzes off-target effects and translational constraints—this article updates with new benchmarks and storage guidance.

Conclusion & Outlook

DIDS is a validated chloride channel blocker with well-defined application parameters in cancer, neuroprotection, and vascular physiology. Its quantitative benchmarks, mechanistic specificity, and translational relevance are supported by peer-reviewed data. Limitations—including solubility, storage, and tissue penetration—must be considered for reproducible results. Future research will further delineate DIDS’s selectivity and expand its use in combinatorial therapies and disease models. For authoritative sourcing and ordering, visit the DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) product page.